Effects of High-Dose Resveratrol in Non-Diabetic Obese Males

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The primary aim of our study was to examine the effects of two weeks of oral resveratrol on resting energy expenditure and insulin sensitivity in non-diabetic obese male subjects. Secondary variables included plasma lipid subfraction, blood pressure and glycated hemoglobin (HbA1c).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Khoo Teck Puat Hospital
• Collaborator: National Medical Research Council (NMRC), Singapore
• Treatments: Resveratrol

Criteria

Inclusion Criteria:

• Ability to give informed consent

• Obese Chinese Male

• Age 21 to 55 yrs old

• No diabetes mellitus

• BMI of 30 kg/m2 or more during screening

Exclusion Criteria:

• Unwilling to abstain from ingesting large quantities of resveratrol-containing foods (eg. red wine, nuts)

• Cancer diagnosis that is currently under treatment, is clinically detectable, or that has been treated within the past 5 years

• Terminal disease or on palliative care

• Current excessive alcohol intake (>21 units per week for men; 14 units per week for women)

• Known diabetes mellitus

• Past history of unexplained hypoglycemia

• Past or current history of strokes

• History of any grape allergy

• On alternative or traditional medications

• Treated with another investigational drug within last 6 months

• Poorly controlled hypertension (SBP >/= 160 or DBP >/= 100) within last one month

• ALT and/or AST > 1.5 times above upper limit of normal within last 6 months

• GFR < 50 ml/min/1.73m2 (MDRD equation) within last 6 months

• Staff of Department of Medicine, Khoo Teck Puat Hospital